Hepcidin-25 in diabetic chronic kidney disease is predictive for mortality and progression to end stage renal disease

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Wagner, Martin ^a,b   Ashby, Damien R ^c   Kurtz, Caroline ^a   Alam, Ahsan ^d   Busbridge, Mark ^c   Raff, Ulrike ^e   Zimmermann, Josef ^a   Heuschmann, Peter U ^a,b   Wanner, Christoph ^a   Schramm, Lothar ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; ERYTHROPOIETIN; HEMOGLOBIN; HEPCIDIN; HEPCIDIN 25; UNCLASSIFIED DRUG; HEPCIDIN 25, HUMAN;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; END STAGE RENAL DISEASE; FEMALE; FERRITIN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HORMONE BLOOD LEVEL; HUMAN; INFLAMMATION; IRON METABOLISM; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEINURIA; RADIOIMMUNOASSAY; RISK FACTOR; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETIC NEPHROPATHY; METABOLISM; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

AGED; COHORT STUDIES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HEPCIDINS; HUMANS; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928544590     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123072     Document Type: Article

References (49)

1. El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005; 67(4):1483-8. PMID: 15780101
2. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004; 66(3):1131-8. PMID: 15327408
3. Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. JAmSocNephrol. 2005; 16(11):3403-10. PMID: 16162813
4. Bassi R, Trevisani A, Tezza S, Ben Nasr M, Gatti F, Vergani A, et al. Regenerative therapies for diabetic microangiopathy. Experimental diabetes research. 2012; 2012:916560. Epub 2012/04/27. doi: 10.1155/2012/916560 PMID: 22536216; PubMed Central PMCID: PMC3321284.
5. Weiss G, Goodnough LT. Anemia of chronic disease. NEnglJMed. 2005; 352(10):1011-23. PMID: 15758012
6. Stockmann C, Fandrey J. Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. Clinical and experimental pharmacology & physiology. 2006; 33(10):968-79. Epub 2006/09/28. doi: 10.1111/j.1440-1681.2006.04474.x PMID: 17002676.
7. Kidney Disease: Improving Global Outcomes Anemia Working G. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney IntSuppl. 2012; 2:279-335. PMID: 25018943
8. Ritz E, Haxsen V. Diabetic nephropathy and anaemia. EurJClinInvest. 2005; 35 Suppl 3:66-74. PMID: 16281961
9. Cullis J. Anaemia of chronic disease. ClinMed. 2013; 13(2):193-6. doi: 10.7861/clinmedicine.13-2-193 PMID: 23681872
10. Means RT Jr., Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992; 80(7):1639-47. Epub 1992/10/11. PMID: 1391934.
11. Ferrucci L, Guralnik JM, Bandinelli S, Semba RD, Lauretani F, Corsi A, et al. Unexplained anaemia in older persons is characterised by low erythropoietin and low levels of pro-inflammatory markers. BrJ Haematol. 2007; 136(6):849-55. PMID: 17341272
12. McGill JB, Bell DS. Anemia and the role of erythropoietin in diabetes. J Diabetes Complications. 2006; 20(4):262-72. PMID: 16798479
13. Thomas MC, Tsalamandris C, Macisaac R, Jerums G. Functional erythropoietin deficiency in patients with Type 2 diabetes and anaemia. DiabetMed. 2006; 23(5):502-9. PMID: 16681558
14. Ganz T. Molecular control of iron transport. Journal of the American Society of Nephrology: JASN. 2007; 18(2):394-400. Epub 2007/01/19. doi: 10.1681/ASN.2006070802 PMID: 17229910.
15. Zhao N, Zhang AS, Enns CA. Iron regulation by hepcidin. JClinInvest. 2013; 123(6):2337-43. doi: 10.1172/JCI67225 PMID: 23722909
16. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009; 122(2-3):78-86. doi: 10.1159/000243792 PMID: 19907145
17. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306(5704):2090-3. PMID: 15514116
18. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011; 117(17):4425-33. doi: 10.1182/blood-2011-01-258467 PMID: 21346250
19. Wagner M, Ashby D. Hepcidin - a well-known iron biomarker with prognostic implications in chronic kidney disease. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association. 2013; 28(12):2936-9. Epub 2013/09/21. doi: 10.1093/ndt/gft330 PMID: 24046195.
20. Abdel-Khalek MA, El-Barbary AM, Essa SA, Ghobashi AS. Serum hepcidin: a direct link between anemia of inflammation and coronary artery atherosclerosis in patients with rheumatoid arthritis. JRheumatol. 2011; 38(10):2153-9. doi: 10.3899/jrheum.110339 PMID: 21885483
21. Niihata K, Tomosugi N, Uehata T, Shoji T, Mitsumoto K, Shimizu M, et al. Serum hepcidin-25 levels predict the progression of renal anemia in patients with non-dialysis chronic kidney disease. NephrolDialTransplant. 2012; 27(12):4378-85. doi: 10.1093/ndt/gfs322 PMID: 22833619
22. van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2013; 28(12):3062-71. Epub 2012/11/14. doi: 10.1093/ndt/gfs488 PMID: 23147161.
23. Wagner M, Alam A, Zimmermann J, Rauh K, Koljaja-Batzner A, Raff U, et al. Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease. ClinJAmSocNephrol. 2011; 6(7):1573-9. doi: 10.2215/CJN.00380111 PMID: 21734083
24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann InternMed. 1999; 130(6):461-70. PMID: 10075613
25. Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012; 307(18):1941-51. doi: 10.1001/jama.2012.3954 PMID: 22570462
26. Busbridge M, Griffiths C, Ashby D, Gale D, Jayantha A, Sanwaiya A, et al. Development of a novel immunoassay for the iron regulatory peptide hepcidin. British journal of biomedical science. 2009; 66(3):150-7. Epub 2009/10/21. PMID: 19839227.
27. Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem. 1998; 44(1):45-51. PMID: 9550557
28. Belesley DA, Kuh E. and Welsh R.E. Regression Diagnostics: Identifying Influential Data and Sources of Collinearity: John Wiley & Sons, NY; 1980.
29. Freund RJaL, Ramon C. SAS System for Regression, Third Edition: SAS Institute Inc., Cary, NC; 2000.
30. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(6):1906-10. Epub 2005/02/03. doi: 10.1073/pnas.0409808102 PMID: 15684062; PubMed Central PMCID: PMC548537.
31. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. JClin Invest. 2004; 113(9):1271-6. PMID: 15124018
32. Roy CN, Mak HH, Akpan I, Losyev G, Zurakowski D, Andrews NC. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood. 2007; 109(9):4038-44. Epub 2007/01/16. doi: 10.1182/blood-2006-10-051755 PMID: 17218383; PubMed Central PMCID: PMC1874566.
33. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. JClinInvest. 2002; 110(7):1037-44. PMID: 12370282
34. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. AnnuRevMed. 2011; 62:347-60. doi: 10.1146/annurev-med-050109-142444 PMID: 20887198
35. Nakanishi T, Hasuike Y, Otaki Y, Kida A, Nonoguchi H, Kuragano T. Hepcidin: another culprit for complications in patients with chronic kidney disease? NephrolDialTransplant. 2011; 26(10):3092-100. doi: 10.1093/ndt/gfr410 PMID: 21785039
36. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008; 112(10):4292-7. Epub 2008/08/12. doi: 10.1182/blood-2008-02-139915 PMID: 18689548.
37. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. NEnglJMed. 2010; 363(12):1146-55. doi: 10.1056/NEJMoa1005109 PMID: 20843249
38. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica. 2010; 95(3):505-8. doi: 10.3324/haematol.2009.013136 PMID: 19833632
39. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009; 75(9):976-81. doi: 10.1038/ki.2009.21 PMID: 19212416
40. Soriano S, Gonzalez L, Martin-Malo A, Rodriguez M, Aljama P. C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3-5 patients. Clin-Nephrol. 2007; 67(6):352-7. PMID: 17598370
41. Fiorina P, Vergani A, Bassi R, Niewczas MA, Altintas MM, Pezzolesi MG, et al. Role of podocyte B7-1 in diabetic nephropathy. Journal of the American Society of Nephrology: JASN. 2014; 25(7):1415-29. Epub 2014/03/29. doi: 10.1681/ASN.2013050518 PMID: 24676639; PubMed Central PMCID: PMC4073425.
42. Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. Journal of the American Society of Nephrology: JASN. 2012; 23(3):507-15. Epub 2012/01/24. doi: 10.1681/ASN.2011060627 PMID: 22266663; PubMed Central PMCID: PMC3294310.
43. Mostovaya IM, Bots ML, van den Dorpel MA, Goldschmeding R, den Hoedt CH, Kamp O, et al. Left ventricular mass in dialysis patients, determinants and relation with outcome. Results from the COnvective TRansport STudy (CONTRAST). PloS one. 2014; 9(2):e84587. Epub 2014/02/08. doi: 10.1371/journal. pone.0084587 PMID: 24505249; PubMed Central PMCID: PMC3914777.
44. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011; 305(15):1553-9. doi: 10.1001/jama.2011.451 PMID: 21482743
45. Wang L, Trebicka E, Fu Y, Ellenbogen S, Hong CC, Babitt JL, et al. The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease. InflammBowelDis. 2012; 18(1):112-9.
46. Smith TG, Talbot NP. Prolyl hydroxylases and therapeutics. AntioxidRedoxSignal. 2010; 12(4):431-3.
47. Doria A, Niewczas MA, Fiorina P. Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy? Seminars in nephrology. 2012; 32(5):437-44. Epub 2012/10/16. doi: 10.1016/j.semnephrol.2012.07.006 PMID: 23062984; PubMed Central PMCID: PMC3474984.
48. Ford BA, Eby CS, Scott MG, Coyne DW. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney international. 2010; 78(8):769-73. Epub 2010/07/30. doi: 10.1038/ki.2010.254 PMID: 20668427.
49. Peters HP, Rumjon A, Bansal SS, Laarakkers CM, van den Brand JA, Sarafidis P, et al. Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. NephrolDialTransplant. 2012; 27(10):3923-9. doi: 10.1093/ndt/gfs164 PMID: 22815544